Literature DB >> 8773594

Neurodegenerative disorders with extensive tau pathology: a comparative study and review.

M B Feany1, D W Dickson.   

Abstract

Many neurodegenerative disorders with onset in mid to late adult life present diagnostic challenges to clinicians and pathologists alike. A distinguishing neuropathological feature has traditionally been the presence or absence of neurofibrillary tangles. Recent biochemical and molecular biological studies have identified the microtubule-binding protein tau as the predominant component of these and related inclusions, and have provided powerful new reagents for the study of neurodegenerative diseases. Several diseases previously considered distinct pathophysiological entities contain similar tau-immunoreactive lesions, but qualitative and regional anatomical differences in vulnerability can differentiate the disorders. Comparison of tau-immunoreactive lesions in three relatively uncommon neurodegenerative diseases-progressive supranuclear palsy, Pick's disease, and corticobasal degeneration-illustrates the types of analyses that demonstrate unexpected pathological similarities, but also fundamental differences between these disorders. These results have important implications for the differential diagnosis of disorders containing tau-immunoreactive lesions, including Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8773594     DOI: 10.1002/ana.410400204

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  50 in total

1.  Interleukin-1 promotes expression and phosphorylation of neurofilament and tau proteins in vivo.

Authors:  J G Sheng; S G Zhu; R A Jones; W S Griffin; R E Mrak
Journal:  Exp Neurol       Date:  2000-06       Impact factor: 5.330

2.  Aberrant detergent-insoluble excitatory amino acid transporter 2 accumulates in Alzheimer disease.

Authors:  Randall L Woltjer; Kevin Duerson; Joseph M Fullmer; Paramita Mookherjee; Allison M Ryan; Thomas J Montine; Jeffrey A Kaye; Joseph F Quinn; Lisa Silbert; Deniz Erten-Lyons; James B Leverenz; Thomas D Bird; David V Pow; Kohichi Tanaka; G Stennis Watson; David G Cook
Journal:  J Neuropathol Exp Neurol       Date:  2010-07       Impact factor: 3.685

Review 3.  Vaccines for Alzheimer's disease: how close are we?

Authors:  Christopher Janus
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

4.  Prefibrillar tau oligomers in mild cognitive impairment and Alzheimer's disease.

Authors:  Elliott J Mufson; Sarah Ward; Lester Binder
Journal:  Neurodegener Dis       Date:  2013-09-11       Impact factor: 2.977

5.  17beta-estradiol attenuates glycogen synthase kinase-3beta activation and tau hyperphosphorylation in Akt-independent manner.

Authors:  Hai-Rong Shi; Ling-Qiang Zhu; Shao-Hui Wang; Xin-An Liu; Qing Tian; Qi Zhang; Qun Wang; Jian-Zhi Wang
Journal:  J Neural Transm (Vienna)       Date:  2008-01-24       Impact factor: 3.575

Review 6.  Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.

Authors:  Yoshinari Miyata; John Koren; Janine Kiray; Chad A Dickey; Jason E Gestwicki
Journal:  Future Med Chem       Date:  2011-09       Impact factor: 3.808

Review 7.  Discovery of new lesions in neurodegenerative diseases with monoclonal antibody techniques: is there a non-amyloid precursor to senile plaques?

Authors:  D W Dickson
Journal:  Am J Pathol       Date:  1997-07       Impact factor: 4.307

Review 8.  Regulated phosphorylation and dephosphorylation of tau protein: effects on microtubule interaction, intracellular trafficking and neurodegeneration.

Authors:  M L Billingsley; R L Kincaid
Journal:  Biochem J       Date:  1997-05-01       Impact factor: 3.857

Review 9.  Trends in the molecular pathogenesis and clinical therapeutics of common neurodegenerative disorders.

Authors:  Yahya E Choonara; Viness Pillay; Lisa C Du Toit; Girish Modi; Dinesh Naidoo; Valence M K Ndesendo; Sibongile R Sibambo
Journal:  Int J Mol Sci       Date:  2009-06-03       Impact factor: 6.208

Review 10.  Chaperone signalling complexes in Alzheimer's disease.

Authors:  John Koren; Umesh K Jinwal; Daniel C Lee; Jeffrey R Jones; Cody L Shults; Amelia G Johnson; Laura J Anderson; Chad A Dickey
Journal:  J Cell Mol Med       Date:  2009-04       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.